Who is eligible for clinical trial NCT05357612?

Participants must meet the protocol's inclusion criteria for Neurodegenerative Diseases. The stated age range is 50 Years to 85 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT05357612 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-08-04

Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases (NCT05357612)

🟢 Recruiting Phase4 💊 Investigational Drug / Biologic Sponsor: Vanderbilt University Medical Center

🩺 Plain-English Summary (8th-Grade Level)

It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-\[18F\]MH.MZ in both populations.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (4 items) and avoid the listed exclusions (10 items).

Location: Vanderbilt University Medical Center — Nashville, Tennessee

Age range: 50 Years to 85 Years

🧪 Interventions in This Study

Pimavanserin (DRUG)

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Patient arm - clinical diagnosis of Parkinson disease, diffuse Lewy body disease, multiple systems atrophy, Huntington's Disease, Frontotemporal Dementia, and other variants
Healthy arm - age and gender matched to patient arm
Psychosis (presence of hallucinations or delusions) starting after the diagnosis of Parkinson's disease, occurring at least weekly for 4 weeks, severe enough to warrant treatment.
Study partner available for study visits

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Prior stroke or other uncontrolled serious neurological or medical illness
Contra-indication or inability to tolerate MRI scan
Use of serotonergic medications in the last 6 weeks
Incapable of providing independent consent.
Pregnant or breastfeeding women
psychosis due to a metabolic, toxic, or primary psychiatric disease
Deemed unable to complete neurocognitive testing
For PD Participants: current or prior use of pimavanserin
Use of antipsychotics in the last 2 weeks

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

Vanderbilt University Medical Center — Nashville, Tennessee

📞 Contact the Study Coordinator

Phone: (615) 421-0569

Email: levi.f.pettit@vumc.org

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Neurodegenerative Diseases

Home Exercise for Individuals with Neurodegenerative Disease — Baltimore, Maryland

Explore by condition: All Neurodegenerative Diseases clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗